Where can I buy Librela for dogs?

Librela must be prescribed and administered by your vet. Talk to your vet about getting your dog started on Librela.

What is Librela for dogs?

Librela is the first and only anti-NGF monoclonal antibody for the control of OA pain in dogs. Librela is administered in the clinic as a once-monthly injection and was approved as safe and effective in clinical studies. Librela is an alternative treatment option to daily oral medications. Your veterinarian can determine if Librela is right for your dog.

Give Your Dog More Days of Play

Librela offers long-lasting pain relief with a once-a-month injection administered by your vet professional.¹

Osteoarthritis (OA), or arthritis, is a painful, chronic condition of the joints. Pain from OA can severely affect the health and well-being of your dog.² Although we can’t cure OA, we can control the pain it causes, which can help your dog be more active and improve their overall quality of life.^3-6

Ask your vet about the newest osteoarthritis injection for dogs.

Are you missing the signs of your dog's OA pain? Take our quiz to find out.

Dog OA Pain Quiz

One Monthly Injection of Librela Can Reduce Your Dog's OA Pain

By reducing OA pain and helping to restore mobility, your dog can feel better and you can get back to the activities you both love.^1,3-6

Why Librela for Dogs?

By decreasing OA pain, Librela can increase your dog's activity and improve their quality of life.^1,3-6
Effectively controls canine OA pain with a once-a-month injection given by a veterinary professional.¹
Available in Europe since 2021, with nearly 25 million doses distributed.⁷

: Librela is a monoclonal antibody that specifically targets a key driver of OA pain. It works to reduce pain signals, making it easier for your dog to move and play.^3-6

In addition to reducing pain, it is important that your dog is at an ideal weight and is getting the proper amount of exercise as part of a complete pain management plan. Your veterinarian will work with you on an OA pain management plan that best suits your dog. Ask your veterinarian if Librela is right for your dog.
: Although the effects of Librela may not be seen until after the second injection, some dogs will show a decrease in signs of OA pain as soon as seven days after the first injection.^1,5,6 Individual responses will vary.
: Before considering Librela, it’s always best to tell your veterinarian about any medication that your dog is receiving. Your veterinarian will decide what medications are safe to give at the same time as Librela.

What Is Dog OA Pain?

OA is a chronic and painful condition that causes your dog to hurt all the time if left untreated.²

OA is a type of arthritis that happens when protective tissue in the joints is worn down, causing bones to rub against one another.
Dogs of all ages, sizes, and breeds can have OA pain—it’s not just a condition seen in older dogs.⁸
OA decreases your dog’s willingness to play, affects their quality of life, and makes it hard for you to do the things you love together.

Nearly 40% of dogs show signs of OA Pain

Vet-Approved Support

Librela FAQ

Librela must be prescribed and administered by your vet professional. Talk to your vet about getting your dog started on Librela.

Librela is given once a month. When you begin treatments with Librela, you should be able to schedule regular monthly visits with your vet for future doses.

Yes. Librela is approved as safe for dogs, but a conversation with your vet is the best way to confirm that Librela is right for your dog. For example, Librela should not be used in dogs with a sensitivity to the active ingredient, bedinvetmab. Librela also shouldn't be used in dogs who are pregnant, breeding, or lactating. The most common side effects that occurred in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.¹

After the approval of Librela, additional side effects were reported. Not all side effects are reported to FDA/CVM. It is not always possible to reliably estimate side effect frequency or establish a causal relationship to product exposure and these additional side effects. Additional side effects in dogs reported are:

Neurological: ataxia, seizures, paresis, proprioception deficits, paralysis
General: anorexia, lethargy, recumbency
Urinary: polydipsia, polyuria/pollakiuria, urinary incontinence
Gastrointestinal: vomiting, diarrhea
Musculoskeletal: muscle weakness, muscle tremors, lameness

In some cases, death (including euthanasia) has been reported as an outcome of the side effects listed above. Always have a conversation with a veterinarian to consider the risks and benefits of adding any treatment.

Although the effects of Librela may not be seen until after the second dose, some dogs may show a decrease in the signs of pain as soon as seven days after the first dose.¹ With once-monthly injections, Librela provides long-lasting control of OA pain.^1,5,6

View Full FAQ

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.

INDICATIONS: For the control of pain associated with osteoarthritis in dogs.

See the Client Information Sheet for more information about Librela.

References:

Librela (bedinvetmab injection). Prescribing information. NADA 141-562. Zoetis Inc; March 2023.
Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78. doi:10.1016/j. tvjl.2019.07.001.
Brown DC, Boston RC, Coyne JC, Farrar JT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. 2007;68(6):631-637. doi:10.2460/ajvr.68.6.631.
Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the Canine Brief Pain Inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-1283. doi:10.2460/ javma.233.8.1278.
Corral, Maria J., et al. "A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis." Veterinary anaesthesia and analgesia 48.6 (2021): 943-955. https://doi.org/10.1016/j.vaa.2021.08.001
Michels GM et al. Vet Anaesth Analg. 2023;50(5):446-458. doi:10.1016/j.vaa.2023.06.003
Zoetis data on file. December 31, 2024.
Anderson KL et al. Front Vet Sci. 2020;7:200. doi:10.3389/fvets.2020.00220
Wright A et al. J Small Anim Pract. 2022;63(8):609-618. doi:10.1111/jsap.13500

ZPC-02734R5

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

Control Dog OA Pain With Monthly, Long-Lasting Librela